Clarify Pharma PLC Notice of Annual General Meeting (5956C)

TIDMPSYC

RNS Number : 5956C

Clarify Pharma PLC

13 June 2023

13 June 2023

Clarify Pharma PLC

("Clarify Pharma" or "the Company")

Notice of Annual General Meeting

Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, announces that it will hold its Annual General Meeting ('AGM') on Wednesday 5 July 2023 at 11 am BST, at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR.

Further details on the arrangement for this year's AGM are set out in the Notice of AGM, which together with the Form of Proxy, have been posted to shareholders today. The Notice of AGM will shortly also be available on the Company's website.

For further information, please visit www.clarifypharma.com or contact:

 
       Clarify Pharma 
       Jon Bixby                    via First Sentinel 
        Executive Chairman 
                             ------------------------- 
       First Sentinel 
                             ------------------------- 
       Corporate Adviser 
        Brian Stockbridge           [phone] 
                             ------------------------- 
 

About Clarify Pharma PLC:

Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation. www.clarifypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUOSSROKUNAAR

(END) Dow Jones Newswires

June 13, 2023 10:51 ET (14:51 GMT)